Science and Technology News and Videos
Preliminary results from a three-year study into the effects of Eli Lilly's weight loss injectables Zepbound and Mounjaro found that they're extremely effective at reducing the risk of developing diabetes., Lilly boasted that weekly shots of tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced the risk of the onset of diabetes by 94 percent in pre-diabetic trial subjects who were overweight or obese.
In Lilly's three-year SURMOUNT-1 trial, which is currently in its third phase, 1,032 people with pre-diabetes took either tirzepatide or a placebo for 176 weeks, followed by a 17-week cooling-off period where the drug wasn't taken.
Beyond appearing to lower the risk of developing diabetes, people who took active tirzepatide during the SURMOUNT-1 trial also experienced a nearly 23 percent decline in average body weight, which likely contributed to the lowered diabetes risk., Lilly warns that the most common adverse effects experienced by subjects in the trial were gastrointestinal. The drugmaker advises those interested in taking tirzepatide to talk to their doctors about these common side effects.
Lilly also added that anyone on oral birth control pills should also discuss changing medications because it's been shown toAs with every other new piece of news to come from these groundbreaking new weight loss meds, though, these findings have to be understood through the context of the manyDevelopmentsEminem Slaps Affiliate Link for Much-Criticized Teletherapy Startup on End of New VideoSubscribe to our daily newsletter to keep in touch with the subjects shaping our future.
I understand and agree that registration on or use of this site constitutes agreement to its User Agreement and Privacy Policy
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
I lost 55 pounds on Mounjaro in six months — here's why I quit taking it“I was desperate for something to move the needle, and Mounjaro was literally a last resort for me,” explained Natalie Wilgus.
Read more »
Mounjaro/Zepbound Drastically Cuts Risk Of Type 2 Diabetes, Eli Lilly Report SuggestsArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study FindsTirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows.
Read more »
Eli Lilly's Zepbound reduces type 2 diabetes risk, study showsEli Lilly announced results of a study in which weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among certain adults.
Read more »
Eli Lilly weight loss drug reduces diabetes riskPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
Getting Enough Of This Brain-Critical Nutrient Reduces Your Dementia Risk By 32%Just up your intake of good ol' vitamin D.
Read more »